Enlivex halts oncology research, lays off 50% of staff; Moderna warns against TRC Capital mini-tender
Enlivex Therapeutics is stopping all clinical development of its oncology drug candidates as well as laying off 50% of its workforce …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
